Federation Des Caisses Desjardins Du Quebec Celldex Therapeutics, Inc. Transaction History
Federation Des Caisses Desjardins Du Quebec
- $18.4 Billion
- Q4 2024
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 1,544 shares of CLDX stock, worth $30,771. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,544
Previous 1,544
-0.0%
Holding current value
$30,771
Previous $52,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CLDX
# of Institutions
196Shares Held
60.7MCall Options Held
960KPut Options Held
675K-
Kynam Capital Management, LP Princeton, NJ5.06MShares$101 Million8.11% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$93.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.88MShares$77.4 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.75MShares$74.8 Million1.82% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.56MShares$70.9 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $932M
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...